| ²é¿´: 379 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
zbw2014гæ (³õÈëÎÄ̳)
|
[ÇóÖú]
Çó·Ò룬¶àл¶àл
|
||
|
The lack of cross-reactivity of AN100226m and natalizumab to rodent ¦Á4 (see Section 2.1 and Section 2.2 of Report 2.6.2, Pharmacology Written Summary) prevented testing of most safety pharmacology parameters in standard test systems as the test systems for these studies are all rodent-based. |
» ²ÂÄãϲ»¶
277Çóµ÷¼Á ÊýÒ»104·Ö
ÒѾÓÐ13È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
336Çóµ÷¼Á£¬Ò»Ö¾Ô¸Öпƴó
ÒѾÓÐ6È˻ظ´
071000ÉúÎïѧ£¬Ò»Ö¾Ô¸ÉîÛÚ´óѧ296·Ö£¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ19È˻ظ´
274Çóµ÷¼ÁÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
277¹¤¿ÆÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
283·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
295Çóµ÷¼Á
ÒѾÓÐ16È˻ظ´
ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
zbw2014: ½ð±Ò+5, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-09-01 22:51:36
zbw2014: ½ð±Ò+5, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-09-01 22:51:36
| ÓÉÓÚ¿¹ÌåAN100226mºÍnatalizumab¶ÔÄö³ÝÀදÎÕâÀïÖ÷ÒªÊÇָСÊ󣩦Á4ûÓн»²æ·´Ó¦£¨²ÎÕÕ±¨¸æ2.6.2ÖеÄ2.1½ÚºÍ2.2½Ú£¬Ò©ÀíѧÊéÃæ×ܽᣩ£¬¾Í×èÖ¹ÁËÀûÓñê×¼²âÊÔϵͳ¼ì²â×ȫҩÀíѧ²ÎÊýµÄ²âÊÔ£¬ÒòΪÕâÀàÑо¿µÄ²âÊÔϵͳ¶¼ÊÇ»ùÓÚÄö³ÝÀදÎïµÄ¡£ |
2Â¥2014-09-01 22:46:30














»Ø¸´´ËÂ¥